Seattle Genetics ‘Guided Missile’ Blasts Rare Lymphoma

A drug from Seattle Genetics Inc. and Takeda Pharmaceutical Co. used a double-barreled approach to wipe out malignancy in patients with a deadly form of lymphoma, a study found.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.